var data={"title":"Estradiol (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Estradiol (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/389290?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=estradiol-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Estradiol (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=estradiol-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Estradiol (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018272\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Endometrial cancer: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\"> There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Close clinical surveillance of all women taking estrogens is important. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be taken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal genital bleeding.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiovascular disease:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease. The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (0.625 mg) alone, relative to placebo.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\"> Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease. The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism (PE), stroke, and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg), relative to placebo.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Breast cancer:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The Women's Health Initiative (WHI) estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Dementia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen-alone therapy should not be used for the prevention of dementia. The WHI Memory Study (WHIMS) estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years and older during 5.2 years of treatment with daily conjugated estrogens (0.625 mg) alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen plus progestin therapy should not be used for the prevention of dementia. The WHIMS estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years or older during 4 years of treatment with daily conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk vs benefits:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In the absence of comparable data, these risks should be assumed to be similar for other doses of conjugated estrogens (with or without medroxyprogesterone acetate) and other dosage forms of estrogens (with or without progestins). Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Secondary exposure (Evamist):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Breast budding and breast masses in prepubertal females and gynecomastia and breast masses in prepubertal males have been reported following unintentional secondary exposure to Evamist by women using this product. In most cases, the condition resolved with removal of Evamist exposure. Women should ensure that children do not come into contact with the site(s) where Evamist is applied. Advise patients to strictly adhere to recommended instructions for use.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018338\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Alora;</li>\n      <li>Climara;</li>\n      <li>Delestrogen;</li>\n      <li>Depo-Estradiol;</li>\n      <li>Divigel;</li>\n      <li>EC-RX Estradiol;</li>\n      <li>Elestrin;</li>\n      <li>Estrace;</li>\n      <li>Estrasorb [DSC];</li>\n      <li>Estrogel;</li>\n      <li>Evamist;</li>\n      <li>Femring;</li>\n      <li>Menostar;</li>\n      <li>Minivelle;</li>\n      <li>Vivelle-Dot</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018339\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Climara;</li>\n      <li>Depo-Estradiol;</li>\n      <li>Divigel;</li>\n      <li>Estrace;</li>\n      <li>Estradot;</li>\n      <li>EstroGel;</li>\n      <li>Menostar;</li>\n      <li>Oesclim;</li>\n      <li>Sandoz-Estradiol Derm 100;</li>\n      <li>Sandoz-Estradiol Derm 50;</li>\n      <li>Sandoz-Estradiol Derm 75</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8090986\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Estrogen Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018394\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Estrasorb has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>General dosing guidelines:</i></b> When treating postmenopausal women, use estrogens for the shortest duration possible at the lowest effective dose consistent with treatment goals. Reevaluate patients as clinically appropriate to determine if treatment is still necessary. Consider use of an estrogen with a progestin in postmenopausal women with a uterus. Women who have had a hysterectomy generally do not need a progestin; however, one may be needed if there is a history of endometriosis. Dosage needs to be adjusted based upon the patient's response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Breast cancer, metastatic:</b> Oral (Estrace): Males and postmenopausal females: 10 mg 3 times/day or (off-label dosing) postmenopausal women: 2 mg 3 times/day (Ellis 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypoestrogenism (female) due to hypogonadism, castration, or primary ovarian failure:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral (Estrace): 1 to 2 mg/day; titrate as necessary to control symptoms using minimal effective dose for maintenance therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Valerate (Delestrogen): 10 to 20 mg every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal (Alora, Climara, Vivelle-Dot): Refer to transdermal product-specific dosing (below).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypoestrogenism (female) due to hypogonadism:</b> IM: Cypionate (Depo-Estradiol): 1.5 to 2 mg monthly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoporosis prevention (females):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral (Estrace): Lowest effective dose has not been determined; doses of 0.5 mg/day in a cyclic regimen for 23 days of a 28-day cycle were used in clinical studies </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal (Alora, Climara, Menostar, Minivelle, Vivelle-Dot): Refer to transdermal product-specific dosing (below).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer, advanced:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Valerate (Delestrogen): 30 mg or more every 1 to 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral (Estrace): 1 to 2 mg 3 times/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vasomotor symptoms associated with menopause: Note:</b> Attempt to taper or discontinue at 3- to 6-month intervals</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral (Estrace): 1 to 2 mg daily, adjusted as necessary to limit symptoms; administration should be cyclic (3 weeks on, 1 week off) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Cypionate (Depo-Estradiol): 1 to 5 mg every 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Valerate (Delestrogen): 10 to 20 mg every 4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Topical emulsion (Estrasorb): 3.48 g applied once daily in the morning </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Topical gel: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Divigel: Initial: 0.25 g/day; adjust dose based on patient response.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Elestrin: Initial: 0.87 g/day applied at the same time each day; adjust dose based on patient response. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">EstroGel: 1.25 g/day applied at the same time each day </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Topical spray (Evamist): Initial: One spray (1.53 mg) per day. Adjust dose based on patient response. Dosing range: 1 to 3 sprays per day. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal (Alora, Climara, Minivelle, Vivelle-Dot): Refer to transdermal product-specific dosing (below).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vaginal ring (Femring): Initial: 0.05 mg intravaginally; following insertion, dose is released daily for 3 months. Usual dose: 0.05 mg to 0.1 mg intravaginally every 3 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vulvar and vaginal atrophy associated with menopause: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Valerate (Delestrogen): 10 to 20 mg every 4 weeks. Attempt to taper or discontinue at 3- to 6-month intervals. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intravaginal: Vaginal ring (Femring): Initial: 0.05 mg intravaginally; following insertion, dose is released daily for 3 months. Usual dose: 0.05 mg to 0.1 mg intravaginally every 3 months. Attempt to taper or discontinue at 3- to 6-month intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral (Estrace): 1 to 2 mg/day; administration should be cyclic (3 weeks on, 1 week off). Attempt to taper or discontinue at 3- to 6-month intervals</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Topical gel (EstroGel): 1.25 g/day applied at the same time each day </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal (Alora, Climara, Vivelle-Dot): Refer to transdermal product-specific dosing (below).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Transdermal product-specific dosing: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Indicated dose may be used continuously in patients without a uterus. Continuous or cyclic schedules (3 weeks on, 1 week off) may be used in women with a uterus (indication and product specific; refer to manufacturers labeling). When changing patients from oral to transdermal therapy, start transdermal patch 1 week after discontinuing oral hormone (may begin sooner if symptoms reappear within 1 week): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypoestrogenism (female) due to hypogonadism, castration, or primary ovarian failure:</b> Adjust dose as necessary to control symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alora: Initial: Initial: Apply 0.05 mg/day patch <i>twice</i> weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Climara: Initial: Apply 0.025 mg/day patch <i>once</i> weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Vivelle-Dot: Initial: Apply 0.025 mg/day patch <i>twice</i> weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteoporosis prevention (female): </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alora, Minivelle, Vivelle-Dot: Initial: Apply 0.025 mg/day patch <i>twice</i> weekly. Adjust dose as necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Climara: Initial: Apply 0.025 mg/day patch <i>once</i> weekly; adjust dosage based on response to therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Estradot [Canadian product]: There are no specific initial dosage recommendations provided in the manufacturer&prime;s labeling; individualize dose per clinical status, bone mineral density (BMD) status and 17-beta estradiol levels (maintain levels at 50 picogram/mL).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Menostar: Apply 0.014 mg/day patch <i>once</i> weekly. In women with a uterus, also administer a progestin for 14 days every 6 to 12 months. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vasomotor symptoms associated with menopause:</b> <b>Note:</b> Adjust dose as necessary. Attempt to taper or discontinue at 3- to 6-month intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alora, Estradot [Canadian product]: Initial: Apply 0.05 mg/day patch <i>twice</i> weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Climara: Initial: Apply 0.025 mg/day patch <i>once</i> weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Minivelle, Vivelle-Dot: Initial: Apply 0.0375 mg/day patch <i>twice</i> weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oesclim [Canadian product]: Initial: Apply 0.025 to 0.05 mg/day patch <i>twice</i> weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vulvar and vaginal atrophy associated with menopause:</b> <b>Note:</b> Adjust dose as necessary. Attempt to taper or discontinue at 3- to 6-month intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alora: Initial: Apply 0.05 mg/day patch <i>twice</i> weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Climara: Initial: Apply 0.025 mg/day patch <i>once</i> weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Vivelle-Dot: Initial: Apply 0.0375 mg/day patch <i>twice </i>weekly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018395\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25065138\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">For most products, there are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25065139\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated with hepatic dysfunction or disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018425\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EC-RX Estradiol: 0.4% (30 g, 60 g); 0.6% (30 g, 60 g) [contains cetearyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Emulsion, Transdermal, as hemihydrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Estrasorb: 4.35 mg/1.74 g (1.74 g [DSC]) [contains polysorbate 80, soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Divigel: 0.25 mg/0.25 g (1 ea); 0.5 mg/0.5 g (1 ea); 1 mg/g (1 g) [contains propylene glycol, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Elestrin: 0.06% (26 g) [contains edetate disodium, propylene glycol, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Estrogel: 0.06% (50 g) [contains alcohol, usp, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oil, Intramuscular, as cypionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depo-Estradiol: 5 mg/mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oil, Intramuscular, as valerate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Delestrogen: 10 mg/mL (5 mL) [contains chlorobutanol (chlorobutol), sesame oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Delestrogen: 20 mg/mL (5 mL); 40 mg/mL (5 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (5 mL [DSC]); 20 mg/mL (5 mL); 40 mg/mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch Twice Weekly, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alora: 0.025 mg/24 hr (1 ea, 8 ea); 0.05 mg/24 hr (1 ea, 8 ea); 0.075 mg/24 hr (1 ea, 8 ea); 0.1 mg/24 hr (1 ea, 8 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Minivelle: 0.025 mg/24 hr (8 ea); 0.0375 mg/24 hr (8 ea); 0.05 mg/24 hr (8 ea); 0.075 mg/24 hr (8 ea); 0.1 mg/24 hr (8 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vivelle-Dot: 0.025 mg/24 hr (1 ea, 8 ea); 0.0375 mg/24 hr (1 ea, 8 ea); 0.05 mg/24 hr (1 ea, 8 ea); 0.075 mg/24 hr (1 ea, 8 ea); 0.1 mg/24 hr (1 ea, 8 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.025 mg/24 hr (8 ea); 0.0375 mg/24 hr (8 ea); 0.05 mg/24 hr (1 ea, 8 ea); 0.075 mg/24 hr (1 ea, 8 ea); 0.1 mg/24 hr (8 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch Weekly, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Climara: 0.025 mg/24 hr (4 ea); 0.0375 mg/24 hr (4 ea); 0.05 mg/24 hr (1 ea, 4 ea); 0.06 mg/24 hr (4 ea); 0.075 mg/24 hr (4 ea); 0.1 mg/24 hr (1 ea, 4 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Menostar: 14 mcg/24 hr (4 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.025 mg/24 hr (1 ea, 4 ea); 0.0375 mg/24 hr (4 ea); 0.05 mg/24 hr (1 ea, 4 ea); 0.06 mg/24 hr (4 ea); 0.075 mg/24 hr (4 ea); 0.1 mg/24 hr (1 ea, 4 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ring, Vaginal, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Femring: 0.05 mg/24 hr (1 ea); 0.1 mg/24 hr (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Evamist: 1.53 mg/spray (8.1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Estrace: 0.5 mg, 1 mg, 2 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg, 1 mg, 2 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018341\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49280524\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">EC-RX Estradiol is a compounding kit. Refer to manufacturer's labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46782848\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patch Twice Weekly, Transdermal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Estradot: 0.025 mg/24 hr, 0.037 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oesclim: 0.025 mg/24 hr, 0.037 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44524571\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Estrasorb has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018398\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">The use of a progestin should be considered when administering estrogens to postmenopausal women with a uterus.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection formulation: Intramuscular use only.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Estradiol cypionate: Shake or gently warm vial to redissolve crystals that may have formed during storage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Estradiol valerate: Should be injected into the upper outer quadrant of the gluteal muscle; administer with a dry needle (solution may become cloudy with wet needle).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Emulsion (Estrasorb): For topical use only; not for ophthalmic, oral, or vaginal use. Do not apply to face or breasts. Apply to clean, dry skin while in a sitting position. Contents of two pouches (total 3.48 g) are to be applied individually, once daily in the morning. Apply contents of first pouch to left thigh; massage into skin of left thigh and calf until thoroughly absorbed. Apply contents of second pouch to the right thigh; massage into skin of right thigh and calf until thoroughly absorbed. Wash hands with soap and water after application. Allow skin to dry before covering legs with clothing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel: Apply to clean, dry, unbroken skin at the same time each day. Wash hands after application. Gel is flammable; avoid fire or flame until skin is dry.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Divigel: Do not apply to face, breasts, vaginal area or irritated skin. The entire contents of packet should be applied to right or left upper thigh each day (alternate sites). Apply over an area ~5 x 7 inches. Do not wash application site for 1 hour. Allow gel to dry before dressing. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Elestrin: Do not apply to breasts or vaginal area. The entire dose should be applied to upper arm and shoulder area using two fingers to spread gel. Allow skin to dry for &ge;5 minutes prior to dressing. Prior to first use, pump must be primed. After priming, the pump contains 30 metered doses; discard pump after 30 doses even though container may not be empty. If &gt;1 dose is needed, wait 5 seconds before pumping next dose. To avoid secondary exposure, do not allow others to contact the application site for 2 hours after gel is applied. Allow at least 2 hours between applying gel and going swimming. Wait at least 25 minutes before applying sunscreen to application area. When sunscreen and gel are applied to the same site for &gt;7 consecutive days, the absorption of estradiol is increased; do not apply sunscreen to an area where the gel was applied for &ge;7 consecutive days. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EstroGel: Do not apply to breasts or vaginal area. Apply dose into the palm of hand and then apply gel to the other arm, from the wrist to the shoulder. Spread gel as thinly as possible over one arm but do not massage or rub in gel. Allow skin to dry for 5 minutes before dressing. Prior to first use, pump must be primed. After priming, the pump contains 32 daily doses (50 g canister) or 14 daily doses (25 g canister). Discard pump after allotted doses even though container may not be empty. To avoid secondary exposure, do not allow others to contact the application site for &ge;1 hour after gel is applied. Wait as long as possible between applying gel and going swimming. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Spray: Evamist: Prior to first use, prime pump by spraying 3 sprays with the cover on. To administer dose, hold container upright and vertical and rest the plastic cone flat against the skin while spraying. Spray to the inner surface of the forearm, starting near the elbow. If more than one spray is needed, apply to adjacent but not overlapping areas. Apply at the same time each day. Allow spray to dry for ~2 minutes; do not rub into skin; do not cover with clothing until dry. Do not wash application site for at least 60 minutes. Apply to clean, dry, unbroken skin. Do not apply to skin other than that of the forearm. Make sure that children do not come in contact with any skin area where the drug was applied. If contact with children is unavoidable, wear a garment with long sleeves that covers the site of application. If direct exposure should occur, wash the child in the area of exposure with soap and water as soon as possible. Solution contained in the spray is flammable; avoid fire, flame, or smoking until spray has dried. If needed, sunscreen should be applied ~1 hour prior to application of Evamist.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Transdermal patch: General administration instructions (also refer to product labeling): Apply patch immediately after removing from protective pouch to lower abdomen or buttocks. Apply to clean, dry, healthy skin that is free of oil, powder, or lotion. Avoid waistline or other areas where tight clothing may rub the patch off; do not apply to breasts. After application, hold patch in place using palm of hand for 10 seconds. Rotate application sites allowing a 1-week interval between applications at a particular site. In general, if patch falls off, the same patch may be reapplied or a new system may be used for the remainder of the dosing interval. When replacing patch, reapply to a new site. Remove patch slowly after use to avoid skin irritation. If any adhesive remains on the skin after removal, first allow skin to dry for 15 minutes, then gently rub area with an oil-based cream or lotion. Dispose of any used or unused patches by folding adhesive ends together, replace in pouch or sealed container, and discard properly in trash away from children and pets.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Climara, Menostar: Swimming, bathing, or wearing patch while in a sauna have not been studied</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Vaginal ring: Exact positioning is not critical for efficacy; however, patient should not feel anything once inserted. In case of discomfort, ring should be pushed further into vagina. If ring is expelled prior to 90 days, it may be rinsed off with warm water and reinserted. Ensure proper vaginal placement of the ring to avoid inadvertent urinary bladder insertion. If vaginal infection develops, Femring may remain in place during local treatment of a vaginal infection. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132514\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. For IM preparation, NIOSH recommends double gloving, a protective gown, and ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator). Double gloving and a gown are required during IM administration. NIOSH recommends double gloving, a protective gown, and (if liquid that could splash) eye/face protection for administration of a topical product; if there is potential for inhalation, respiratory protection is recommended (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018342\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, metastatic:</b> Treatment of metastatic breast cancer (palliation) in appropriately selected men and postmenopausal women.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypoestrogenism (female ):</b> Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoporosis prevention (female):</b> Prevention of postmenopausal osteoporosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: For use only in women at significant risk of postmenopausal osteoporosis; consider use of nonestrogen medications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer, advanced:</b> Treatment of androgen dependent advanced prostatic cancer (palliation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vasomotor symptoms associated with menopause:</b> Treatment of moderate to severe vasomotor symptoms associated with menopause.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vulvar and vaginal atrophy associated with menopause:</b> Treatment of moderate to severe vulvar and vaginal atrophy associated with menopause.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: When used solely for the treatment of vulvar and vaginal atrophy, topical vaginal products should be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018336\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Alora may be confused with Aldara</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Elestrin may be confused with alosetron</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older (independent of diagnosis or condition) due to their carcinogenic potential (breast and endometrium) and lack of cardioprotection or cognitive protection in older women. Low-dose intravaginal estrogen (vaginal creams or tablets) are <i>acceptable</i> for dyspareunia, lower urinary tract infections, and other vaginal symptoms. Of note, women with a history of breast cancer not responding to non-hormonal therapies are advised to discuss the risks/benefits of low dose vaginal estrogen (estradiol less than 25 mcg twice weekly) with their health care provider (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Estrogens (oral and topical patch products only), with or without progestins, are identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vivelle: Brand name for estradiol [US and multiple international markets, but also the brand name for ethinyl estradiol and norgestimate [Austria]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018351\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">Frequency not always defined. Some adverse reactions observed with estrogen and/or progestin combination therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Edema (10% to 13%), hypertension (3% to 7%), cerebrovascular accident, deep vein thrombosis, local thrombophlebitis, myocardial infarction, pulmonary thromboembolism, retinal thrombosis, thrombophlebitis, venous thromboembolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Headache (9% to 50%), pain (6% to 13%), depression (1% to 11%), anxiety (4% to 10%), dizziness (&le;8%), migraine (7%), nipple pain (1% to 7%), hypoesthesia (3%),  chorea, dementia, exacerbation of epilepsy, irritability, mood disorder, nervousness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash (7% to 9%), pruritus (4% to 7%), chloasma, erythema multiforme, erythema nodosum, localized erythema (transdermal patch), loss of scalp hair, skin discoloration (melasma), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Weight gain (4% to 9%), hot flash (6%), hirsutism (&le;5%), change in libido, change in menstrual flow (alterations in frequency and flow of bleeding patterns), exacerbation of diabetes mellitus, exacerbation of porphyria, fibrocystic breast changes, fluid retention, galactorrhea, hypocalcemia, increased serum triglycerides, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain (6% to 16%), dyspepsia (3% to 9%), constipation (4% to 7%), flatulence (3% to 7%), nausea (3% to 7%), gastroenteritis (3% to 4%), diarrhea (3%), abdominal cramps, bloating, carbohydrate intolerance, gallbladder disease, pancreatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Mastalgia (5% to 35%), vaginal hemorrhage (33%), breast tenderness (3% to 17%), endometrium disease (15%), breakthrough bleeding (6% to 11%), leukorrhea (2% to 11%), abnormal uterine bleeding (4% to 10%), breast hypertrophy (7%), dysmenorrhea (7%), cervical polyp (6%), vulvovaginal candidiasis (6%), urinary tract infection (4% to 6%), change in cervical ectropion, change in cervical secretions, endometrial hyperplasia, nipple discharge, spotting, uterine fibroids (size increased), uterine pain, vaginal discomfort (vaginal ring; burning, irritation, itching), vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Hemorrhagic eruption, hypercoagulability state, malignant neoplasm of breast, ovarian cancer</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Cholestatic jaundice, exacerbation of hepatic hemangioma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction (4% to 5%), anaphylactoid reaction, anaphylaxis, angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Infection (3% to 12%), fungal infection (3% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Application site reaction (gel, spray, transdermal patch &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia (4% to 12%), back pain (3% to 11%), weakness (8%), limb pain (7% to 8%), myalgia (5% to 6%), neck pain (3% to 6%), arthropathy (4% to 5%), exacerbation of systemic lupus erythematosus, leg cramps</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Conjunctivitis (3%), change in corneal curvature (steepening), contact lens intolerance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Otitis media (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Nasopharyngitis (4% to 20%), upper respiratory tract infection (6% to 17%), flu-like symptoms (8% to 13%), sinusitis (4% to 13%), sinus headache (9% to 11%), bronchitis (6% to 8%), sinus congestion (7%), pharyngitis (2% to 7%), rhinitis (2% to 6%), cough (3% to 4%), asthma (3%), exacerbation of asthma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Accidental injury (7% to 14%), cyst (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Postmarketing and/or case reports: Abnormal gait, abnormal hepatic function tests, aphasia, blindness, bowel obstruction (vaginal ring), bradyphrenia, chest pain, cholecystitis, cholelithiasis, dyspnea, emotional lability, fatigue, genitourinary complaint (inadvertent ring insertion into the bladder should be considered with unexplained urinary complaints), hemorrhage, hepatitis, hyperhidrosis, hypermenorrhea, ischemic heart disease, lip swelling, local irritation (transdermal patch), localized erythema (transdermal patch), malaise, mechanical complication of genitourinary device (ring adherence to vaginal or bladder wall), meningioma, muscle spasm, myoclonus, night sweats, oral paresthesia, ovarian cyst, palpitations, paresthesia, peripheral edema, pharyngeal edema, phlebitis, portal vein thrombosis, purpura, retinal vein occlusion, soft tissue sarcoma (malignant mesenchymoma), swollen tongue, tachyphylaxis, toxic shock syndrome (vaginal ring), transient ischemic attacks, unstable angina pectoris, uterine enlargement, uterine neoplasm, vaginal discharge</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018348\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angioedema, anaphylactic reaction, or hypersensitivity to estradiol or any component of the formulation; undiagnosed abnormal genital bleeding; DVT or PE (current or history of); active or history of arterial thromboembolic disease (eg, stroke, MI); breast cancer (known, suspected or history of), except in appropriately selected patients being treated for metastatic disease; estrogen-dependent tumor (known or suspected); hepatic impairment or disease; known protein C, protein S, antithrombin deficiency or other known thrombophilic disorders; pregnancy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for estrogens is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): <b>Note:</b> May be dosage form dependent (consult product labeling): Breastfeeding; endometrial hyperplasia; active thrombophlebitis; partial or complete loss of vision or diplopia due to ophthalmic vascular disease; presence or history of hepatic tumors (benign or malignant); porphyria; classical migraine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018349\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis: Anaphylaxis requiring emergency medical management has been reported and may develop at any time during therapy. Angioedema involving the face, feet, hands, larynx, and tongue has also been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Breast cancer: <b>[US Boxed Warning]: Based on data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal women using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA).</b> This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson 2012). An increase in abnormal mammogram findings has also been reported with estrogen alone or in combination with progestin therapy. Estrogen use may lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dementia: <b>[US Boxed Warning]: Estrogens with or without progestin should not be used to prevent dementia. In the Women&rsquo;s Health Initiative Memory Study (WHIMS), an increased incidence of probable dementia was observed in women &ge;65 years of age taking CE alone or in combination with MPA.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Endometrial cancer: <b>[US Boxed Warning]: The use of unopposed estrogen in women with a uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding.</b> There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. The risk of endometrial cancer is dose and duration dependent; risk appears to be greatest with use &ge;5 years and may persist following discontinuation of therapy. The use of a progestin is not generally required when low doses of estrogen are used locally for vaginal atrophy (NAMS 2012; NAMS 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Endometriosis: Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestin in women with residual endometriosis posthysterectomy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Inherited thrombophilia: Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho 2010; van Vlijmen 2011). Use is contraindicated in women with protein C, protein S, antithrombin deficiency, or other known thrombophilic disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased in women with preexisting hypertriglyceridemia; discontinue if pancreatitis occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ovarian cancer: Postmenopausal estrogens with or without progestins may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration, route, or dose of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Asthma: Use caution with asthma; may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease:<b>[US Boxed Warning]: Estrogens with or without progestin should not be used to prevent cardiovascular disease. Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT) and stroke has been reported with CE and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) has been reported with CE with MPA in postmenopausal women 50 to 79 years of age.</b> Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected. Use is contraindicated in women with active DVT, PE, active arterial thromboembolic disease or a history of these conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diseases exacerbated by fluid retention: Use caution with diseases which may be exacerbated by fluid retention, including cardiac or renal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Epilepsy: Use caution with epilepsy; may exacerbate disease. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic dysfunction: Estrogens are poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur. Use is contraindicated with hepatic impairment or disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic hemangiomas: Use caution with hepatic hemangiomas; may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hereditary angioedema: Exogenous estrogens may exacerbate angioedema symptoms in women with hereditary angioedema.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypoparathyroidism: Use caution with hypoparathyroidism; estrogen-induced hypocalcemia may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Migraine: Use caution with migraine; may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Porphyria: Use caution with porphyria; may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; SLE: Use caution with SLE; may exacerbate disease. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Prior to puberty, estrogens may cause premature closure of the epiphyses. Premature breast development, vaginal bleeding, and vaginal cornification may be induced in girls. Modification of the normal puberty process may occur in boys.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Surgical patients: Whenever possible, estrogens should be discontinued at least 4 to 6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Chlorobutanol: Some products may contain chlorobutanol (a chloral derivative) as a preservative, which may be habit forming.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tartrazine: Some products may contain tartrazine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Topical emulsion, gel: Absorption of the topical emulsion (Estrasorb) and topical gel (Elestrin) is increased by application of sunscreen; do not apply sunscreen within close proximity of estradiol. Application of sunscreen or lotion after EstroGel decreases absorption of estradiol; the effect of applying sunscreen or lotion prior to Estrogel has not been studied. Application of Divigel with sunscreen has not been evaluated. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Topical spray: When sunscreen is applied ~1 hour prior to the topical spray (Evamist), no change in absorption was observed (estradiol absorption was decreased when sunscreen is applied 1 hour after Evamist).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vaginal ring: Use may not be appropriate in women with narrow vagina, vaginal stenosis, vaginal infections, cervical prolapse, rectoceles, cystoceles, or other conditions which may increase the risk of vaginal irritation, ulceration, or increase the risk of expulsion. Ring should be removed in case of ulceration, erosion, or adherence to vaginal wall; do not reinsert until healing is complete. Ensure proper vaginal placement of the ring to avoid inadvertent urinary bladder insertion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influence these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Osteoporosis use: For use only in women at significant risk of osteoporosis and for who other nonestrogen medications are not considered appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Risks vs benefits: <b>[US Boxed Warning]: Estrogens with or without progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals and risks for the individual woman.</b> Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women&rsquo;s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied. <b>Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.</b> Women who are early in menopause, who are in good cardiovascular health, and who are at low risk for adverse cardiovascular events can be considered candidates for estrogen with or without progestin therapy for the relief of menopausal symptoms (ACOG 565 2013). Use of a transdermal product should be considered over an oral agent in women requiring systemic therapy who have risk factors for venous thromboembolism or coronary heart disease (ACOG 556 2013; Schenck-Gustafsson 2011; Tremollieres 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Secondary exposure: Estradiol may be transferred to another person following skin-to-skin contact with the application site. <b>[US Boxed Warning]: Breast budding and breast masses in prepubertal females and gynecomastia and breast masses in prepubertal males have been reported following unintentional contact with application sites of women using topical estradiol (Evamist). Patients should strictly adhere to instructions for use in order to prevent secondary exposure. In most cases, conditions resolved with removal of estradiol exposure.</b> If unexpected changes in sexual development occur in prepubertal children, the possibility of unintentional estradiol exposure should be evaluated by a health care provider. Discontinue if conditions for the safe use of the topical spray cannot be met.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vulvar and vaginal atrophy use: Moderate-to-severe symptoms of vulvar and vaginal atrophy include vaginal dryness, dyspareunia, and atrophic vaginitis. When used solely for the treatment of vulvar and vaginal atrophy, topical vaginal products should be considered. Use caution applying topical products to severely atrophic vaginal mucosa. Use of a progestin is normally not required when low-dose estrogen is applied locally and only for this purpose (NAMS 2012; NAMS 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018356\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (major), CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018357\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9120&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Estrogen Derivatives may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anthrax Immune Globulin (Human): Estrogen Derivatives may enhance the thrombogenic effect of Anthrax Immune Globulin (Human). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.  Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">C1 inhibitors: Estrogen Derivatives may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inducers (Moderate): May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproterone: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dantrolene: Estrogen Derivatives may enhance the hepatotoxic effect of Dantrolene. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dehydroepiandrosterone: May enhance the adverse/toxic effect of Estrogen Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Exemestane: Estrogen Derivatives may diminish the therapeutic effect of Exemestane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: Estrogen Derivatives may diminish the therapeutic effect of Hemin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immune Globulin: Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Estrogen Derivatives may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: Estrogen Derivatives may decrease the serum concentration of LamoTRIgine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Lenalidomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mivacurium: Estrogen Derivatives may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the thrombogenic effect of Estrogen Derivatives. Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pomalidomide: May enhance the thrombogenic effect of Estrogen Derivatives. Management: Canadian pomalidomide labeling recommends caution with use of hormone replacement therapy and states that hormonal contraceptives are not recommended. US pomalidomide labeling does not contain these specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Somatropin: Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.  Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: Estrogen Derivatives may increase the serum concentration of Succinylcholine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Estrogen Derivatives may increase the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible.  If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018361\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Folic acid absorption may be decreased. Routine use of ethanol increases estrogen level and risk of breast cancer; may also increase the risk of osteoporosis. Management: Avoid ethanol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018343\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018344\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">In general, the use of estrogen and progestin as in combination hormonal contraceptives has not been associated with teratogenic effects when inadvertently taken early in pregnancy. These products are contraindicated for use during pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018347\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The Canadian labeling contraindicates use in breast-feeding women.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Estrogens are excreted in breast milk and have been shown to decrease the quantity and quality of human milk. The US labeling recommends that caution be used if administered to breast-feeding women. Monitor the growth of the infant closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018397\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ensure adequate calcium and vitamin D intake when used for the prevention of osteoporosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018403\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Routine physical examination that includes blood pressure and Papanicolaou smear, breast exam, mammogram. Monitor for signs of endometrial cancer in female patients with a uterus. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal genital bleeding. Monitor for loss of vision, sudden onset of proptosis, diplopia, migraine; signs and symptoms of thromboembolic disorders; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; thyroid function in patients on thyroid hormone replacement therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Menostar: When used in a woman with a uterus, endometrial sampling is recommended at yearly intervals or when clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Menopausal symptoms, vulvar and vaginal atrophy: Assess need for therapy at 3- to 6-month intervals </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prevention of osteoporosis: Bone density measurement</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Monitoring of FSH and serum estradiol is not useful when managing vasomotor symptoms associated with menopause or vulvar and vaginal atrophy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018378\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the principle intracellular human estrogen and is more potent than estrone and estriol at the receptor level; it is the primary estrogen secreted prior to menopause. Following menopause, estrone and estrone sulfate are more highly produced. Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system; estrogen replacement reduces elevated levels of these hormones in postmenopausal women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018385\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed from the gastrointestinal tract, mucous membranes, and the skin. Average serum estradiol concentrations (C<sub>avg</sub>) vary by product</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Injection: Estradiol valerate and estradiol cypionate are absorbed over several weeks following IM injection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Topical: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Alora: C<sub>avg</sub>: 41 to 98 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Climara: C<sub>avg</sub>: 22 to 106 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Divigel: C<sub>avg</sub>: 9.8 to 30.5 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Elestrin: C<sub>avg</sub>: 15.4 to 39.2 pg/mL; Exposure increased by 55% with application of sunscreen 10 minutes prior to dose </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Estrasorb: Mean serum concentration on day 22 of therapy: ~35 to 65 pg/mL; Exposure increased by ~38% with application of sunscreen 10 minutes prior to estradiol 8.7 mg and exposure increased by ~46% when sunscreen was applied 25 minutes after estradiol application.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Estrogel: C<sub>avg</sub> on day 14 of therapy: 28.3 pg/mL. C<sub>max</sub> of estradiol is altered by repeated daily application (for 7 days) of sunscreen (decreased by 16%) or lotion (increased by 73%) when applied 1 hour after the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Evamist: C<sub>avg</sub>: 19.6 to 30.9 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Menostar: C<sub>avg</sub>: 13.7 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Vivelle-Dot: C<sub>avg</sub>: 34 to 104 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vaginal: Femring: Rapid during the first hour following application, then declines to a steady rate over 3 months; C<sub>avg</sub>: 40.6 to 76 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely distributed; high concentrations in the sex hormone target organs</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Bound to sex hormone-binding globulin and albumin </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; partial metabolism via CYP3A4 enzymes; estradiol is reversibly converted to estrone and estriol; oral estradiol also undergoes enterohepatic recirculation by conjugation in the liver, followed by excretion of sulfate and glucuronide conjugates into the bile, then hydrolysis in the intestine and estrogen reabsorption. Sulfate conjugates are the primary form found in postmenopausal women. With transdermal application, less estradiol is metabolized leading to higher circulating concentrations of estradiol and lower concentrations of estrone and conjugates.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine (as estradiol, estrone, estriol and their glucuronide and sulfate conjugates) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018427\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Divigel Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg/0.25gm (1): $4.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/0.5 g (1): $4.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/g (1 g): $4.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Elestrin Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.52 MG/0.87 GM (0.06%) (26 g): $115.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Estrogel Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75 MG/1.25 GM (0.06%) (50 g): $145.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oil</b> (Delestrogen Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (5 mL): $159.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (5 mL): $224.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (5 mL): $372.37</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oil</b> (Depo-Estradiol Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (5 mL): $126.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oil</b> (Estradiol Valerate Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (5 mL): $144.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (5 mL): $239.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch weekly</b> (Climara Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025 mg/24 hrs (4): $150.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.0375 mg/24 hrs (4): $150.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05 mg/24 hrs (1): $37.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.06 mg/24 hrs (4): $150.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.075 mg/24 hrs (4): $150.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/24 hrs (1): $37.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch weekly</b> (Estradiol Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025 mg/24 hrs (4): $88.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.0375 mg/24 hrs (4): $88.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05 mg/24 hrs (4): $88.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.06 mg/24 hrs (4): $88.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.075 mg/24 hrs (4): $88.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/24 hrs (4): $88.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch weekly</b> (Menostar Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">14 mcg/24 hrs (4): $194.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, twice-weekly</b> (Alora Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025 mg/24 hrs (1): $15.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05 mg/24 hrs (1): $16.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.075 mg/24 hrs (1): $17.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/24 hrs (1): $17.69</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, twice-weekly</b> (Estradiol Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025 mg/24 hrs (8): $90.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.0375 mg/24 hrs (8): $90.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05 mg/24 hrs (8): $90.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.075 mg/24 hrs (8): $108.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/24 hrs (8): $90.83</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, twice-weekly</b> (Minivelle Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025 mg/24 hrs (8): $198.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.0375 mg/24 hrs (8): $198.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05 mg/24 hrs (8): $198.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.075 mg/24 hrs (8): $198.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/24 hrs (8): $198.05</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, twice-weekly</b> (Vivelle-Dot Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025 mg/24 hrs (8): $145.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.0375 mg/24 hrs (8): $145.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05 mg/24 hrs (8): $145.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.075 mg/24 hrs (8): $145.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/24 hrs (8): $145.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ring</b> (Femring Vaginal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05 mg/24 hrs (1): $532.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/24 hrs (1): $567.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Evamist Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.53 mg/spray (8.1 mL): $141.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Estrace Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $623.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $623.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $800.41</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Estradiol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $55.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $68.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $94.15</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390228\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aerodiol (AT, BE);</li>\n      <li>Bedol (GB, IE);</li>\n      <li>Climaderm (BR, VE);</li>\n      <li>Climara (AT, AU, BB, BE, BG, CH, CZ, EE, FI, FR, IE, KR, LU, LV, NZ, PH, PL, RU, TH, ZA);</li>\n      <li>Dermestril (BE, CZ, DE, FI, IT, PT);</li>\n      <li>Dermestril Septem (FR);</li>\n      <li>Divigel (CH, DK, EE, IN, LV, MY, SE, SG, TH, TW);</li>\n      <li>Enadiol (CL, PY);</li>\n      <li>Estra Gel (TW);</li>\n      <li>Estrade (TW);</li>\n      <li>Estraderm (CO, DK, ES, SE, VN);</li>\n      <li>Estraderm MX (AU, IN, PT, SA, SG);</li>\n      <li>Estraderm TTS (AE, AT, BF, BH, BJ, CI, CO, CY, CZ, DE, EG, ET, FR, GB, GH, GM, GN, GR, IL, IQ, IR, IT, JO, KE, KR, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NZ, OM, PL, PY, QA, SC, SD, SL, SN, SY, TN, TR, TZ, UG, YE, ZA, ZM);</li>\n      <li>Estradiol Depot (KR);</li>\n      <li>Estradot (AU, BR, CZ, DE, ES, FI, GB, GR, IE, NO, PT, SE, UY);</li>\n      <li>Estramon (UA);</li>\n      <li>Estrapatch (FR);</li>\n      <li>Estreva (DE, HK, PE, PT, TR, VN);</li>\n      <li>Estreva Gel (PE);</li>\n      <li>Estrifam (DE);</li>\n      <li>Estro-Pause (ZA);</li>\n      <li>Estrofem (AR, AT, AU, BE, BH, BR, CH, CN, CZ, DK, EE, FI, FR, HK, HU, IL, IN, IS, JO, KR, KW, LB, LT, LU, LV, NZ, PH, RU, SA, SG, SI, TH, UY);</li>\n      <li>Estrofem Forte (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Estrogel (VE);</li>\n      <li>Estrozhel (UA);</li>\n      <li>Evopad (ES);</li>\n      <li>Evorel (AR, BB, BM, BS, DK, GY, IE, IL, JM, NL, NO, PR, SE, SR, TT, UY, ZA);</li>\n      <li>Evorel Conti (BB, BM, BS, GY, JM, NL, PR, SR, TT);</li>\n      <li>Fem (CN);</li>\n      <li>Femanest (SE);</li>\n      <li>Fematab (IE);</li>\n      <li>Fematrix (GB, IE);</li>\n      <li>Feminova (BE);</li>\n      <li>Femsept (FR);</li>\n      <li>Femseven (GB, IE);</li>\n      <li>Femtran (AU, NZ);</li>\n      <li>Ginoderm Gel (PY);</li>\n      <li>Gynokadin (DE);</li>\n      <li>Gynova (BD);</li>\n      <li>GynPolar (DE);</li>\n      <li>Kliovance (AU);</li>\n      <li>Lindisc (AR, CO, CR, EC, GT, HN, NI, PA, SV);</li>\n      <li>Linoladiol N (EE);</li>\n      <li>Lumelin 2 (TW);</li>\n      <li>Menodin-Retard (CO);</li>\n      <li>Menorest (AU, DE, IT);</li>\n      <li>Merimono (DE);</li>\n      <li>Oesclim (FR);</li>\n      <li>Oestrodose (IL);</li>\n      <li>Postmenop (TH);</li>\n      <li>Preda (KR);</li>\n      <li>Primogyn Depot (ZA);</li>\n      <li>Progyluton 21 (ZW);</li>\n      <li>Progynon (CH, DE, DK, IT, SE);</li>\n      <li>Progynon Depot (IN, TW);</li>\n      <li>Progynova (AR, AT, AU, BE, BZ, CL, CN, CO, CR, DO, ES, FI, FR, GT, HN, ID, IL, IN, KR, LK, MT, MY, NI, NZ, PA, PE, PH, PL, RU, SE, SG, SV, UY, VE, ZA);</li>\n      <li>Prohinova (UA);</li>\n      <li>Prosu 2 (TW);</li>\n      <li>Provames (FR);</li>\n      <li>Pyvihel (UA);</li>\n      <li>Sandrena (BR, CH);</li>\n      <li>Sandrena Gel (AU, DE);</li>\n      <li>Sisare Gel (DE);</li>\n      <li>Thais (FR);</li>\n      <li>Tradelia (DE);</li>\n      <li>Valiera (VN);</li>\n      <li>Vivelle-Dot (BE, DK);</li>\n      <li>Vivelledot (FR);</li>\n      <li>Zumenon (AT, BE, GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists. ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. <i>Obstet Gynecol</i>. 2013;121:887-890.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/23635705/pubmed\" target=\"_blank\" id=\"23635705\">23635705</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee Opinion No. 565: Hormone therapy and heart disease. <i>Obstet Gynecol</i>. 2013;121:1407-1410.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/23812486/pubmed\" target=\"_blank\" id=\"23812486\">23812486</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alora (estradiol transdermal system) [prescribing information]. Parsippany, NJ: Actavis; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc.</i> 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson GL, Chlebowski RT, Aragaki AK, et al, &quot;Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,&quot; <i>Lancet Oncol,</i> 2012,13(5):476-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/22401913/pubmed\" target=\"_blank\" id=\"22401913\">22401913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson GL, Limacher M, Assaf AR, et al, &quot;Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial.&quot; <i>JAMA</i>, 2004, 291(14):1701-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/15082697/pubmed\" target=\"_blank\" id=\"15082697\">15082697</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chlebowski RT, Kuller LH, Prentice RL, et al, &quot;Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,&quot; <i>N Engl J Med</i>, 2009, 360(6):573-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/19196674/pubmed\" target=\"_blank\" id=\"19196674\">19196674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Climara (estradiol transdermal system) [prescribing information]. Whippany, NJ: Bayer; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Delestrogen (estradiol valerate) [prescribing information]. Spring Valley, NY: Par Pharmaceutical; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depo-Estradiol (estradiol cypionate) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Company; October 2006.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeSancho MT, Dorff T, and Rand JH, &quot;Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,&quot; <i>Blood Coagul Fibrinolysis</i>, 2010, 21(6):534-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/20581664/pubmed\" target=\"_blank\" id=\"20581664\">20581664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Divigel (estradiol gel) [prescribing information]. Sayreville, NJ; Vertical Pharmaceuticals; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elestrin (estradiol gel) [prescribing information]. Somerset NJ; Meda Pharmaceuticals; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ellis MJ, Gao F, Dehdashti F, et al, &ldquo;Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor-Positive, Aromatase Inhibitor-Resistant Advanced Breast Cancer: A Phase 2 Randomized Study,&rdquo; <i>JAMA</i>, 2009, 302(7):774-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/19690310/pubmed\" target=\"_blank\" id=\"19690310\">19690310</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Estrace (estradiol) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Estrace (estradiol) [product monograph]. Mississauga, Ontario, Canada: Acerus Pharmaceuticals; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Estraderm (estradiol) [prescribing information]. East Hanover, PA: Novartis Pharmaceuticals; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Estradot (estradiol) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Estrasorb (estradiol topical emulsion) [prescribing information]. Bridgewater, NJ: Medicis; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    EstroGel (estradiol gel) [prescribing information]. Herndon, VA: ASCEND Therapeutics; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Evamist (estradiol transdermal spray) [prescribing information]. Minneapolis, MN: Perrigo; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Femring (estradiol acetate) [prescribing information]. Rockaway, NJ: Warner Chilcott (US) LLC; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Femtrace (estradiol acetate) [prescribing information]. Irvine, CA: Allergan USA Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hsia J, Langer RD, Manson JE, et al, &quot;Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative,&quot; <i>Arch Intern Med</i>, 2006, 166(3):357-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/16476878/pubmed\" target=\"_blank\" id=\"16476878\">16476878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hulley S, Grady D, Bush T, et al, &ldquo;Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group,&rdquo; <i>JAMA</i>, 1998, 280(7):605-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/9718051/pubmed\" target=\"_blank\" id=\"9718051\">9718051</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menostar (estradiol transdermal system) [prescribing information]. Wayne, NJ: Bayer HealthCare; October 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Minivelle (estradiol transdermal system) [prescribing information]. Miami, FL: Noven Pharmaceuticals; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, et al, &ldquo;Hormone Therapy and Ovarian Cancer,&rdquo; <i>JAMA</i>, 2009, 302(3):298-305.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/19602689/pubmed\" target=\"_blank\" id=\"19602689\">19602689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    North American Menopause Society [NAMS], &quot;The 2012 Hormone Therapy Position Statement of The North American Menopause Society,&quot; <i>Menopause</i>, 2012, 19(3):257-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/22367731/pubmed\" target=\"_blank\" id=\"22367731\">22367731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    North American Menopause Society [NAMS], Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. <i>Menopause</i>. 2013 Sep;20(9):888-902; quiz 903-4. doi: 10.1097/GME.0b013e3182a122c2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/23985562/pubmed\" target=\"_blank\" id=\"23985562\">23985562</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oesclim (estradiol) [product monograph]. Montreal, Quebec, Canada: Searchlight Pharma Inc; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pharmacy Quality Alliance. Use of high-risk medications in the elderly (HRM). http://pqaalliance.org/images/uploads/files/HRM2015.pdf. Published 2015. Accessed October 26, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2002, 288(3):321-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/12117397/pubmed\" target=\"_blank\" id=\"12117397\">12117397</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schenck-Gustafsson K, Brincat M, Erel CT, Gambacciani M, et al. EMAS position statement: Managing the menopause in the context of coronary heart disease. <i>Maturitas</i>. 2011;68(1):94-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/21156341/pubmed\" target=\"_blank\" id=\"21156341\">21156341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shumaker SA, Legault C, Rapp SR, et al, &ldquo;Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2003, 289(20):2651-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/12771112/pubmed\" target=\"_blank\" id=\"12771112\">12771112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stallard S, Litherland JC, Cordiner CM, et al, &ldquo;Effect of Hormone Replacement Therapy on the Pathological Stage of Breast Cancer: Population Based, Cross Sectional Study,&rdquo; <i>BMJ</i>, 2000, 320(7231):348-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/10657329/pubmed\" target=\"_blank\" id=\"10657329\">10657329</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tremollieres F, Brincat M, Erel CT, et al. European Menopause and Andropause Society. EMAS position statement: Managing menopausal women with a personal or family history of VTE. <i>Maturitas</i>. 2011;69:195-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/21489728/pubmed\" target=\"_blank\" id=\"21489728\">21489728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van Vlijmen EF, Veeger NJ, Middeldorp S, et al, &quot;Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,&quot; <i>Blood</i>, 2011, 118(8):2055-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-drug-information/abstract-text/21659542/pubmed\" target=\"_blank\" id=\"21659542\">21659542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vivelle (estradiol transdermal system) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vivelle-Dot (estradiol transdermal system) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9120 Version 249.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8018272\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8018338\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8018339\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8090986\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8018394\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8018395\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F25065138\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F25065139\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8018425\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8018341\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F49280524\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F46782848\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F44524571\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8018398\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132514\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8018342\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8018336\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8018351\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8018348\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8018349\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8018356\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8018357\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F8018361\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8018343\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8018344\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F8018347\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F8018397\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F8018403\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8018378\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8018385\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8018427\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390228\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9120|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=estradiol-systemic-patient-drug-information\" class=\"drug drug_patient\">Estradiol (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=estradiol-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Estradiol (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}